Literatur
-
1
Howell A, Cuzick J, Baum M et al.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Lancet.
2005;
365
60-62
-
2
Goodwin P J, Ennis M, Pritchard K I et al.
Risk of menopause during the frst year after breast cancer diagnosis.
J Clin Oncol.
1999;
17
2365-2370
-
3
Hickey M, Saunders C M, Stuckey B G.
Management of menopausal symptoms in patients with breast cancer: an evidence-based approach.
Lancet Oncol.
2005;
6
687-695
-
4
Col N F, Hirota L K, Orr R K et al.
Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.
J Clin Oncol.
2001;
19
2357-2363
-
5
Modelska K, Cummings S.
Tibolone for postmenopausal women: systematic review of randomized trials.
J Clin Endocrinol Metab.
2002;
87
6-23
-
6
Kenemans P, Speroff L.
Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
Maturitas.
2005;
51
21-28
-
7
Kloosterboer H J.
Tibolone: a steroid with a tissue-speciïfc mode of action.
J Steroid Biochem Mol Biol.
2001;
76
231-238
-
8
DeGooyer M E, Deckers G H, Schoonen W G et al.
Receptor profiling and endocrine interactions of tibolone.
Steroids.
2003;
68
21-30
-
9
Lundström E, Christow A, Kersemaekers W et al.
Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.
Am J Obstet Gynecol.
2002;
186
717-722
-
10
Valdivia I, Campodónico I, Tapia A et al.
Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.
Fertil Steril.
2004;
81
617-623
-
11
Conner P, Christow A, Kersemaekers W et al.
A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined östrogen-progestogen treatment.
Climacteric.
2004;
7
50-58
-
12
Beral V. Million Women Study Collaborators .
Breast cancer and hormone-replacement therapy in the Million Women Study.
Lancet.
2003;
362
419-427
-
13
Opatrny L, Dell'Aniello S, Assouline S et al.
Hormone replacement therapy use and vartiations in the risk of breast cancer.
Br J Obstet Gynaecol.
2008;
115
169-175
-
14
Cummings S R, Ettinger B, Delmas P D et al.
The effects of tibolone in older postmenopausal women.
N Engl J Med.
2008;
359
697-708
-
15
Kroiss R, Fentiman I S, Helmond F A et al.
The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
Br J Obstet Gynaecol.
2005;
112
228-233
-
16
Dimitrakakis C, Keramopoulos D, Vourli G et al.
Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Climacteric.
2005;
8
342-351
-
17
Pollow K, Schaffrath M, Kölbl H et al.
Phase II study of goserelin adjuvant therapy combined with exemestane with or without tibolone in premenopausal women with receptor positive, node negative mammary carcinoma: ADAGIO Study.
Geburtsh Frauenheilk.
2005;
65
612-619
-
18
Kubista E, Planellas Gomez J, Dowset M et al.
Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Clin Cancer Res.
2007;
13
4185-4190
-
19
Bundred N J, Kenemans P, Beckmann M W et al.
Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study.
Cancer Res.
2009;
69
66
-
20
Cline J M, Register T C, Clarkson T B.
Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys.
Menopause.
2002;
9
422-429
-
21
Verheul H A, van Iersel M L, Delbressine L P et al.
Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone.
Drug Metab Dispos.
2007;
35
1105-1111
-
22
Suzuki T, Miki Y, Nakata T et al.
Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma.
J Steroid Biochem Mol Biol.
2003;
86
449-454
-
23
Million Women Study Collaborators .
Breast cancer and hormone-replacement therapy in the Million Women Study.
The Lancet.
2003;
362
419-427
-
24
Holmberg L, Anderson H. for the HABITS steering and data monitoring committees .
HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped.
The Lancet.
2004;
363
453-455
Prof. Dr. med. M. Untch
Chefarzt der Klinik für Gynäkologie und Geburtshilfe und Leiter des Interdisziplinären Brustzentrums · HELIOS-Klinikum Berlin-Buch
Schwanebecker Chaussee 50
13125 Berlin
eMail: michael.untch@helios-kliniken.de
